XML 43 R32.htm IDEA: XBRL DOCUMENT v3.10.0.1
Acquisition of Pelican Therapeutics (Schedule of Purchase Price of Assets and Liabilities) (Details) - USD ($)
6 Months Ended
Jun. 30, 2018
Dec. 31, 2017
Purchase price allocation:    
Goodwill $ 2,189,338 $ 2,189,338
Pelican Therapeutics, Inc. [Member]    
Aggregate consideration:    
Cash consideration 500,000  
Stock consideration 1,052,000  
Contingent consideration 2,385,000  
Total Consideration 3,937,000  
Purchase price allocation:    
Cash acquired 31,199  
In-process R&D 5,866,000  
Goodwill 2,189,338  
Deferred tax liability (2,111,760)  
Net liabilities assumed (1,102,777)  
Fair value of non-controlling interest (935,000)  
Total purchase price $ 3,937,000